Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Albert Weisbrot

Family Medicine Mason, OH Medical Doctor

NPI 1285730077 CMS profile 330867

7451 S Mason Montgomery Road, Suite C, Mason, OH 45040

Open in the dashboard

General payments

$3,237

93 records reported · program years 2019–2023

Research payments

$166,774

Paid to them · 248 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$40,684 paid to institutions, not to them · program years 2019–2023

Through program year 2023, Albert Weisbrot of Mason, OH is reported in the CMS Open Payments database as having received $3,237 across 93 general payments and $166,774 in research payments paid to them. Separately, studies naming them as principal investigator received $40,684 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $170 10
2022 General $204 12
2021 General $146 10
2021 Research $36,495 54
2020 General $136 10
2020 Research $38,252 74
2019 General $2,581 51
2019 Research $92,028 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Weisbrot
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Albert Weisbrot were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Albert Weisbrot Family Medicine median Middle half National median
2019 $2,581 $150 $41–$543 $163
2020 $136 $120 $32–$415 $114
2021 $146 $137 $35–$551 $132
2022 $204 $137 $37–$512 $149
2023 $170 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk AS $1,778 4 payments
  2. Novo Nordisk Inc $346 21 payments
  3. AstraZeneca Pharmaceuticals LP $264 13 payments
  4. Janssen Pharmaceuticals, Inc $240 12 payments
  5. Pfizer Inc. $118 9 payments
  6. Lilly USA, LLC $97 7 payments
  7. Amarin Pharma Inc. $59 4 payments
  8. Amgen Inc. $59 4 payments
  9. E.R. Squibb & Sons, L.L.C. $41 3 payments
  10. Kowa Pharmaceuticals America, Inc. $35 3 payments
  11. Other $202 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,708 88 payments
  2. Travel and Lodging $1,516 3 payments
  3. Education $13 2 payments
Products named General payments · program years 2019–2023
  1. Ozempic $2,052 20 payments
  2. RYBELSUS $250 14 payments
  3. XARELTO $225 10 payments
  4. FARXIGA $195 8 payments
  5. SYMBICORT $161 5 payments
  6. INVOKANA $83 8 payments
  7. TRULICITY $80 6 payments
  8. CHANTIX $75 6 payments
  9. JARDIANCE $62 5 payments
  10. Repatha $59 4 payments
  11. Other $705 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Novo Nordisk AS $166,774 248 payments

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

3,377

Median for Family Practice: 1,826

Drug cost

$262,173

Median for Family Practice: $120,094

Branded share of claims

16.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 53 $62,264
Jardiance Empagliflozin Brand 30 $41,832
Mounjaro Tirzepatide Brand 22 $27,243
Farxiga Dapagliflozin Propanediol Brand 17 $23,241
Januvia Sitagliptin Phosphate Brand 12 $19,355
Repatha Sureclick Evolocumab Brand 15 $17,888
Ubrelvy Ubrogepant Brand 14 $16,421
Ozempic Semaglutide Brand 11 $13,703
Ezetimibe Generic 212 $6,754
Rosuvastatin Calcium Generic 271 $2,714

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$29,630

Medicare's payments for the services billed

Medicare patients

131

Average age 75

Services billed

460

46 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 39%
Ischemic heart disease 35%
Diabetes 33%
Cancer 22%
Heart failure 18%
Atrial fibrillation 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record